Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Search
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Veg Frittata video
Use our recipe card and step-by-step recipe video to learn how to make this delicious, seasonal frittata
What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
Contact Us
Contact our partnering team to discuss your project and learn more about how we can work together.
Micardis®
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
Boehringer partners with NCD Alliance
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
Salmon Fishcakes Video
Learn how to make this light bite that’s vibrant in taste. Crispy on the outside and fluffy on the inside, these fishcakes are a great source of omega-3
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Stroke
Stroke
Boehringer Ingelheim Advances Oncology Research
Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
New biomass power plant Ingelheim
Boehringer Ingelheim produces its own green energy
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Rabies? Not in Mexico!
Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Award: Boehringer Ingelheim is Global Top Employer 2022
Global Top Employer 2022
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award